Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

34.90USD
10:40am EDT
Change (% chg)

$-0.02 (-0.06%)
Prev Close
$34.92
Open
$34.35
Day's High
$35.40
Day's Low
$33.98
Volume
24,952
Avg. Vol
133,153
52-wk High
$39.26
52-wk Low
$14.41

Latest Key Developments (Source: Significant Developments)

La Jolla Pharmaceutical announces pricing of public offering of common stock
Thursday, 23 Mar 2017 08:00am EDT 

La Jolla Pharmaceutical Co : Says public offering of 3.70 million common shares priced at $33.50per share .La Jolla Pharmaceutical Company announces pricing of public offering of common stock.  Full Article

La Jolla Pharmaceutical Co announces proposed underwritten public offering of common stock
Monday, 20 Mar 2017 04:01pm EDT 

La Jolla Pharmaceutical Co : La Jolla Pharmaceutical Company announces proposed underwritten public offering of common stock . La Jolla Pharmaceutical Co - announced its intention to offer and sell $100 million of its common stock in an underwritten public offering .La Jolla Pharmaceutical Co - intends to use net proceeds from underwritten offering for future clinical trials of its drug candidates, among others.  Full Article

La Jolla Pharmaceutical files for mixed shelf of up to $150 million
Friday, 18 Nov 2016 05:46pm EST 

La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Co - files for mixed shelf of up to $150 million - sec filing.  Full Article

La Jolla Pharmaceutical announces financial results
Thursday, 3 Nov 2016 04:10pm EDT 

La Jolla Pharmaceutical Co : Q3 loss per share $1.23 . Q3 earnings per share view -$0.97 -- Thomson Reuters I/B/E/S .La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2016 and recent corporate progress.  Full Article

La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016
Monday, 8 Aug 2016 04:44pm EDT 

La Jolla Pharmaceutical Co : La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016 . Quarterly loss per share $0.90 .Q2 earnings per share view $-0.99 -- Thomson Reuters I/B/E/S.  Full Article

La jolla Pharmaceutical Co reports Q1 loss per share of $0.96
Friday, 6 May 2016 09:00am EDT 

La Jolla Pharmaceutical Co : La jolla pharmaceutical company announces first quarter 2016 financial results and recent corporate progress . Q1 loss per share $0.96 . Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S .Qtrly total revenue $234,000.  Full Article

La Jolla Pharmaceutical Co closes offering of common stock
Tuesday, 15 Sep 2015 04:11pm EDT 

La Jolla Pharmaceutical Co:Closes underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share.Intends to use the net proceeds from the offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering.Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners acted as co-managers for the offering.  Full Article

La Jolla Pharmaceutical Co Receives Orphan Drug Designation for Fibrodysplasia Ossificans Progressiva
Tuesday, 18 Aug 2015 08:05am EDT 

La Jolla Pharmaceutical Co:Receives orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva.U.S. FDA's office of orphan products development has granted La Jolla orphan drug designation for two novel compounds.  Full Article

La Jolla Pharmaceutical Company announces FDA Acceptance of IND for LJPC-401
Tuesday, 11 Aug 2015 08:00am EDT 

La Jolla Pharmaceutical Company:Announces that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug Application (IND) for LJPC-401, La Jolla's novel formulation of hepcidin.Says La Jolla expects to release preliminary results from a Phase 1 clinical trial of LJPC-401 by the end of 2015.  Full Article

La Jolla Pharma announces worldwide license agreements covering LJPC-30Sa and LJPC-30Sb
Wednesday, 5 Aug 2015 09:00am EDT 

La Jolla Pharmaceutical Co:Press release - La Jolla Pharmaceutical Company announces exclusive worldwide license agreements covering ljpc-30sa and ljpc-30sb.Says first license agreement is with the Indiana university research and technology corporation.Says second license agreement is with the iurtc and the university of alabama at Birmingham.Agreements cover use of ljpc-30sa and ljpc-30sb as antimicrobial agents,for potential treatment of rare genetic disorders.  Full Article

More From Around the Web